Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
2.7% for placebo
Phase 2 trial (Lancet 2021) tested cagrilintide 0.3 mg through 4.5 mg/week as monotherapy and reported a clear dose-response, with 10.8% mean weight loss at 4.5 mg/week at 26 weeks
Notably, participants consumed inadequate calories from carbohydrates, adequate calories from protein as a percentage of total calories (though critically insufficient in g/kg/day for muscle preservation), and excess calories from fat
Side effects are not a sign that GLP-1s are not working
Contributes to a healthy body composition
Clinical trials are ongoing, and Novo Nordisk has indicated plans to file for approval
US$ 27.47
US$ 20.03
US$ 29.74
US$ 25.11
